PMID- 28429334
OWN - NLM
STAT- MEDLINE
DCOM- 20170804
LR  - 20180319
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 7
DP  - 2017 Apr
TI  - Thrombolysis of deep vein thrombosis and inhibiting chemotaxis of macrophage by 
      MCP-1 blockage.
PG  - 1695-1701
LID - 12541 [pii]
AB  - OBJECTIVE: Deep vein thrombosis (DVT) is one common vascular complication after 
      trauma or surgery. Macrophage plays an important role in recanalization of 
      thrombosis and monocyte chemotactic protein 1 (MCP-1) has a potent chemotactic 
      role for macrophage. This study investigated the role of MCP-1 and macrophage in 
      DVT thrombolysis. MATERIALS AND METHODS: DVT mice model was established for 
      evaluating thrombosis grades, and divided into DVT, DVT + MCP-1 recombinant 
      protein, and DVT + MCP-1 neutralizing antibody groups. MCP-1 mRNA and protein 
      expression, weight/length ratio of thrombosis were tested at 1, 5, 9 and 15 day 
      after DVT. F4/80 protein expression in thrombosis on day 9 was measured to 
      reflect infiltration of macrophage. RESULTS: DVT model mice had thrombosis grade 
      at 2.47 +/- 0.22 whilst no thrombosis occurred in sham group. DVT group had 
      gradually increased MCP-1 mRNA and protein expression, which reached the peak at 
      day 9, followed by decreased expression. Thrombosis weight/length ratio showed 
      decreasing trends. MCP-1 protein injection significantly elevated MCP-1 
      expression, decreased thrombosis weight/length ratio, and elevated macrophage 
      infiltration. Injection of MCP-1 antibody remarkably decreased MCP-1 expression, 
      elevated thrombosis weight/length ratio and macrophage infiltration. CONCLUSIONS: 
      MCP-1 up-regulation participates in macrophage chemotaxis and thrombolysis after 
      DVT formation. The blockade of MCP-1 weakens its thrombolysis effects.
FAU - Wang, Z-W
AU  - Wang ZW
AD  - Department of Vascular Surgery, The Affiliated Qingdao Hiser hospital of Qingdao 
      University, Qingdao, Shandong Province, China. wenxianhuzxc@163.com.
FAU - Wang, J-J
AU  - Wang JJ
FAU - Zhang, J-Z
AU  - Zhang JZ
FAU - Xue, Z-J
AU  - Xue ZJ
FAU - Miao, J
AU  - Miao J
FAU - Li, L
AU  - Li L
FAU - Hu, W-X
AU  - Hu WX
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Animals
MH  - Chemokine CCL2/antagonists & inhibitors/*immunology
MH  - Chemotaxis
MH  - Macrophages/*immunology
MH  - Mice
MH  - *Thrombolytic Therapy
MH  - Venous Thrombosis/*immunology/therapy
EDAT- 2017/04/22 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/04/22 06:00
PHST- 2017/04/22 06:00 [entrez]
PHST- 2017/04/22 06:00 [pubmed]
PHST- 2017/08/05 06:00 [medline]
AID - 12541 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Apr;21(7):1695-1701.